NASH is a worldwide epidemic disease affecting over 115 million people. Still, NASH remains an underdiagnosed and consequently an underreported disease. Untreated NASH may lead to cirrhosis, liver cancer and liver transplantation.
NASH is the result of the progression of non-alcoholic liver disease (NAFLD). Around 25% of the world population live with NASH. NASH is under-diagnosed.
NASH is significantly associated with the presence of metabolic syndrome conditions such as obesity (70% of patients), type 2 diabetes (75% of patients) and hyperlipidemia (20-80%).
There is a growing concern in the medical community because of the increasing prevalence of NASH in the world population and the potential consequences on health and economy. NAFLD-related liver transplantations are predicted to almost double within the next 20 years.
Patients are Obese
Patients have Type 2 Diabetes